Results 131 to 140 of about 30,994 (308)

Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6‐Month Claims Database Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Tirzepatide is a once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) approved in the US for the treatment of Type 2 diabetes (T2D), weight loss and obstructive sleep apnoea. This study aimed to assess the utilisation and effectiveness of tirzepatide among individuals in a large ...
Theresa Hunter Gibble, Malvika Venkataraman, Donna Mojdami, Carlos Vallarino, Grace Stockbower, Michael Grabner, Mythili Ananth, Karishma Desai   +7 more
wiley   +1 more source

Real‐World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Tirzepatide has demonstrated substantial weight‐loss efficacy in clinical trials, but real‐world evidence from routine digital prescribing remains limited. Methods We conducted a retrospective cohort study of adults initiating tirzepatide for obesity via a UK digital prescribing service between March 2024 and July 2025. Linked order‐
Onayomi Rosenior‐Patten, Zoe Lees, Rebecca Rowe, Safia Hussain, Ehtasham Ahmad, Edward Brooke, Sophie Dix, Catriona Maybury   +7 more
wiley   +1 more source

Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early‐Phase Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The management of the disease of obesity has been transformed by incretin‐based therapies; however, additional and alternative therapeutic strategies are needed to address its biological complexity. This narrative review examines the physiology of amylin and the emerging role of amylin‐based therapies in obesity management.
Abdulhameed Alhazmi, Carel W. le Roux
wiley   +1 more source

Early Weight Regain After GLP‐1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De‐Escalation Strategies

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have transformed the pharmacological management of obesity, producing substantial and sustained weight loss during active treatment. However, discontinuation of therapy is frequently followed by significant weight regain, raising important questions regarding the durability of treatment ...
M. A. Damhof, F. H. van Bruggen, E. N. van Roon   +2 more
wiley   +1 more source

Associations Between BioFire FilmArray Gastrointestinal Panel Results and Clinical Outcomes in Infectious Gastroenteritis

Diagnostics
Background/Objectives: Infectious gastroenteritis (IGE) is a major global health concern due to its high morbidity and healthcare burden. The BioFire FilmArray Gastrointestinal Panel (FA-GIP) enables rapid multiplex detection of enteric pathogens ...
Myeong Joo Lee, Ju Yeong Lee, Suhng Wook Kim   +2 more
doaj   +1 more source

Real‐World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the effectiveness and safety of tirzepatide on glycaemia, weight, and markers of cardiometabolic risk in people with type 1 diabetes and obesity. Materials and Methods This retrospective cohort study compared 142 adults with type 1 diabetes (BMI ≥ 30 kg/m2) initiated on tirzepatide against 50 age‐, sex‐ and BMI‐matched ...
Simon A. Berry, Iona R. Goodman, Eleanor McNally, Jackie Elliott, Ahmed Iqbal   +4 more
wiley   +1 more source

Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Zenagamtide is a novel, unimolecular glucagon‐like peptide‐1 and amylin receptor agonist in development for weight management and Type 2 diabetes. This study investigated the pharmacokinetic (PK) properties, safety and tolerability of zenagamtide in participants with various degrees of renal impairment versus participants with normal ...
Lykke Ida Kaas Oldenburg, Sine Pfeiffer Haugaard, Tobias Karlsson, Victoria Kegel‐Hübner, Mahera Parwez, Christoffer Wiingaard, Anne Flint   +6 more
wiley   +1 more source

Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta‐Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To assess the effect of all the approved classes of medications for type 2 diabetes on Major Adverse Cardiovascular events (MACE) and all‐cause mortality. Methods We performed a pairwise and network meta‐analysis, including randomised controlled trials with a duration of at least 40 weeks, comparing medications versus placebo or an active ...
Giovanni Antonio Silverii, Valerio Velardi, Christian Marinelli, Antonino Lax, Matteo Monami, Edoardo Mannucci   +5 more
wiley   +1 more source

Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess the added value of absolute anthropometric targets alongside percentage weight loss in the clinical management of obesity. Materials and Methods The phase 3a, 68‐week REDEFINE 1 trial randomised adults without diabetes with BMI ≥ 30 kg/m2, or ≥ 27 kg/m2 with ≥ 1 obesity‐related complication, to once‐weekly CagriSema 2.4 mg/2.4 ...
Luca Busetto, Cynthia Osorto Contreras, Mikkel Hovden Christensen, Timothy W. Garvey, Deborah B. Horn, Barbara McGowan, Claire Prener Miller, Volker Schnecke, Carel W. le Roux   +8 more
wiley   +1 more source

NDR2 regulates non-small cell lung cancer cell migration under starvation by supporting autophagosome biogenesis through LC3 and ATG9A regulation

Cell Death Discovery
Non-small cell lung cancer (NSCLC) is characterized by the deregulation of the Hippo kinase NDR2 and high basal autophagic activity. NDR2 promotes autophagy-driven tumor growth in some cancers, but evidence in lung cancer is lacking.
Tiphaine Biojout, Emmanuel Bergot, Jasmine Taylor, Dimitri Leite Ferreira, Nathalie Colloc’h, Marc Riffet, Nicolas Elie, Maelle Guyot, Céline Bazille, Jérôme Levallet, Guénaëlle Levallet   +10 more
doaj   +1 more source